- Home
- IKT vs PLBY Comparison
IKT vs PLBY Comparison
Compare IKT & PLBY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IKT
- PLBY
- Stock Information
- Founded
- IKT 2008
- PLBY 1953
- Country
- IKT United States
- PLBY United States
- Employees
- IKT N/A
- PLBY N/A
- Industry
- IKT Biotechnology: Pharmaceutical Preparations
- PLBY Recreational Games/Products/Toys
- Sector
- IKT Health Care
- PLBY Consumer Discretionary
- Exchange
- IKT Nasdaq
- PLBY Nasdaq
- Market Cap
- IKT 159.2M
- PLBY 142.4M
- IPO Year
- IKT 2020
- PLBY N/A
- Fundamental
- Price
- IKT $2.27
- PLBY $2.01
- Analyst Decision
- IKT Strong Buy
- PLBY Buy
- Analyst Count
- IKT 2
- PLBY 2
- Target Price
- IKT $6.50
- PLBY $2.35
- AVG Volume (30 Days)
- IKT 194.9K
- PLBY 962.4K
- Earning Date
- IKT 03-26-2025
- PLBY 03-26-2025
- Dividend Yield
- IKT N/A
- PLBY N/A
- EPS Growth
- IKT N/A
- PLBY N/A
- EPS
- IKT N/A
- PLBY N/A
- Revenue
- IKT $1.00
- PLBY $124,761,000.00
- Revenue This Year
- IKT N/A
- PLBY N/A
- Revenue Next Year
- IKT N/A
- PLBY N/A
- P/E Ratio
- IKT N/A
- PLBY N/A
- Revenue Growth
- IKT N/A
- PLBY 30.09
- 52 Week Low
- IKT $1.12
- PLBY $0.52
- 52 Week High
- IKT $4.20
- PLBY $2.44
- Technical
- Relative Strength Index (RSI)
- IKT 38.70
- PLBY 65.56
- Support Level
- IKT $1.90
- PLBY $1.63
- Resistance Level
- IKT $2.37
- PLBY $2.44
- Average True Range (ATR)
- IKT 0.25
- PLBY 0.19
- MACD
- IKT -0.07
- PLBY 0.02
- Stochastic Oscillator
- IKT 34.91
- PLBY 50.59
About IKT Inhibikase Therapeutics Inc.
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease ("PD"), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.
About PLBY PLBY Group Inc.
PLBY Group Inc connects consumers around the world with products, services, and experiences to help them look good, feel good, and have fun. PLBY Group serves consumers in four categories: Style and Apparel, Digital Entertainment and Lifestyle, Sexual Wellness, and Beauty and Grooming. It operates through three segments Direct-to-Consumer, Licensing, and Digital Subscriptions and Content. It generates revenue through the sales of products and content services to consumers.